Accelerated cardiac hypertrophy and renal damage induced by angiotensin II in adrenomedullin knockout mice.

Adrenomedullin (AM) is a potent vasodilating and natriuretic peptide that is thought to play important roles in cardiovascular function. Whether or not AM is involved in the development of cardiac hypertrophy and renal damage remains controversial. In the present study, using heterozygote knockout mice of the AM gene (AM +/-), we analyzed the physiological and pathological roles of the endogenous AM gene. There were no differences in body size or heart and kidney weight compared with wild-type (AM +/+) mice. However, angiotensin II (Ang II) infusion resulted in more severe cardiac hypertrophy in AM +/- mice. The increases in the heart weight-to-body weight ratio and wall thickness of the left ventricle were more prominent in the AM +/- mice. Renal dysfunction characterized by decreased creatinine clearance (C(cr)) was more severe in AM +/- after Ang II infusion. These results suggest that AM plays critical roles in the defense mechanism against cardiac hypertrophy and renal dysfunction. An improved understanding of these roles may pave the way to a novel pharmacological approach for the prevention of cardiovascular diseases.

[1]  Daowen Wang,et al.  428. Adrenomedullin Gene Delivery Attenuates Renal Damage and Hypertension in Spontaneous Hypertension Rats , 2004 .

[2]  H. Kurihara,et al.  Targeted disruption of adrenomedullin and alphaCGRP genes reveals their distinct biological roles. , 2003, Hypertension research : official journal of the Japanese Society of Hypertension.

[3]  T. Fujita,et al.  Organ-protective effects of adrenomedullin. , 2003, Hypertension research : official journal of the Japanese Society of Hypertension.

[4]  J. M. Black,et al.  Nephron number and blood pressure in rat offspring with maternal high-protein diet , 2002, Pediatric Nephrology.

[5]  S. Eguchi,et al.  Angiotensin II–Induced Cardiac Hypertrophy and Hypertension Are Attenuated by Epidermal Growth Factor Receptor Antisense , 2002, Circulation.

[6]  H. Nishimatsu,et al.  Role of Endogenous Adrenomedullin in the Regulation of Vascular Tone and Ischemic Renal Injury: Studies on Transgenic/Knockout Mice of Adrenomedullin Gene , 2002, Circulation research.

[7]  N. Kobayashi,et al.  Renoprotective Effect of Chronic Adrenomedullin Infusion in Dahl Salt-Sensitive Rats , 2002, Hypertension.

[8]  KatsuyukiAndo,et al.  Adrenomedullin, an Endogenous Peptide, Counteracts Cardiovascular Damage , 2002 .

[9]  H. Nishimatsu,et al.  Elevated Sympathetic Nervous Activity in Mice Deficient in &agr;CGRP , 2001, Circulation research.

[10]  T. Eto.  A review of the biological properties and clinical implications of adrenomedullin and proadrenomedullin N-terminal 20 peptide (PAMP), hypotensive and vasodilating peptides , 2001, Peptides.

[11]  YasushiImai,et al.  Vascular Abnormalities and Elevated Blood Pressure in Mice Lacking Adrenomedullin Gene , 2001 .

[12]  K. Schlüter,et al.  Specific role for the extracellular signal-regulated kinase pathway in angiotensin II- but not phenylephrine-induced cardiac hypertrophy in vitro , 2001, Pflügers Archiv.

[13]  L. Chao,et al.  Adrenomedullin Gene Delivery Attenuates Hypertension, Cardiac Remodeling, and Renal Injury in Deoxycorticosterone Acetate-Salt Hypertensive Rats , 2000, Hypertension.

[14]  L. Chao,et al.  Human adrenomedullin gene delivery protects against cardiac hypertrophy, fibrosis, and renal damage in hypertensive dahl salt-sensitive rats. , 2000, Human gene therapy.

[15]  R. Nagai,et al.  Hypotension and resistance to lipopolysaccharide-induced shock in transgenic mice overexpressing adrenomedullin in their vasculature. , 2000, Circulation.

[16]  D. Smith,et al.  Adrenomedullin, a multifunctional regulatory peptide. , 2000, Endocrine reviews.

[17]  D. Brooks,et al.  Adrenomedullin decreases extracellular signal-regulated kinase activity through an increase in protein phosphatase-2A activity in mesangial cells. , 2000, European journal of pharmacology.

[18]  V. Dzau,et al.  The renin-angiotensin-aldosterone system: a specific target for hypertension management. , 1999, American journal of hypertension.

[19]  G. Nussdorfer,et al.  Structure–activity relationships of adrenomedullin in the circulation and adrenal gland , 1999, Regulatory Peptides.

[20]  T. Inagami,et al.  Communication between myocytes and fibroblasts in cardiac remodeling in angiotensin chimeric mice. , 1999, The Journal of clinical investigation.

[21]  W. Samson.  Adrenomedullin and the control of fluid and electrolyte homeostasis. , 1999, Annual review of physiology.

[22]  IsseiKomuro,et al.  Pressure Overload Induces Cardiac Hypertrophy in Angiotensin II Type 1A Receptor Knockout Mice , 1998 .

[23]  Y. Koiwaya,et al.  Increased plasma adrenomedullin levels in chronic congestive heart failure. , 1996, American heart journal.

[24]  Y. Hirata,et al.  Increased circulating adrenomedullin, a novel vasodilatory peptide, in sepsis. , 1996, The Journal of clinical endocrinology and metabolism.

[25]  K. Kangawa,et al.  Proadrenomedullin NH(2)-terminal 20 peptide, a new product of the adrenomedullin gene, inhibits norepinephrine overflow from nerve endings. , 1995, The Journal of clinical investigation.

[26]  T. Ishimitsu,et al.  Plasma levels of adrenomedullin, a newly identified hypotensive peptide, in patients with hypertension and renal failure. , 1994, The Journal of clinical investigation.

[27]  K. Kangawa,et al.  Distribution and characterization of immunoreactive rat adrenomedullin in tissue and plasma , 1994, FEBS letters.

[28]  Shokei Kim,et al.  Effect of adrenomedullin on renal hemodynamics and functions in dogs. , 1994, European journal of pharmacology.

[29]  N. Minamino,et al.  Identification and hypotensive activity of proadrenomedullin N‐terminal 20 peptide (PAMP) , 1994, FEBS letters.

[30]  K. Kangawa,et al.  Immunoreactive proadrenomedullin N-terminal 20 peptide in human tissue, plasma and urine. , 1994, Biochemical and biophysical research communications.

[31]  Y. Yazaki,et al.  Angiotensin II receptor antagonist TCV-116 induces regression of hypertensive left ventricular hypertrophy in vivo and inhibits the intracellular signaling pathway of stretch-mediated cardiomyocyte hypertrophy in vitro. , 1994, Circulation.

[32]  K. Kangawa,et al.  Distribution and characterization of immunoreactive adrenomedullin in human tissue and plasma , 1994, FEBS letters.

[33]  K. Kangawa,et al.  Cloning and characterization of cDNA encoding a precursor for human adrenomedullin. , 1993, Biochemical and biophysical research communications.

[34]  K. Kangawa,et al.  Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. , 1993, Biochemical and biophysical research communications.

[35]  Y. Yazaki,et al.  Mechanical loading stimulates cell hypertrophy and specific gene expression in cultured rat cardiac myocytes. Possible role of protein kinase C activation. , 1991, The Journal of biological chemistry.

[36]  K. Baker,et al.  Angiotensin II stimulation of protein synthesis and cell growth in chick heart cells. , 1990, The American journal of physiology.

[37]  D. Levy,et al.  Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. , 1990, The New England journal of medicine.